Aprameya Medtech Secures Exclusive Sales and Marketing Agreement for Products in Western and Southern India
Aprameya Medtech Private Limited, a subsidiary of Aprameya Engineering Limited, has entered into an exclusive sales and marketing agreement with Sonoscape Medical India Private Limited. The arrangement focuses on the domestic market, granting comprehensive rights for several key medical devices across specified regions of India.The partnership covers the exclusive sales and marketing of various products within the Western and Southern Zones of India. These products include MIS Solution (covering models SV-M2K30, SV-M4K30, SV-M4K40, X-2600, SV- M4K120Exp, and SV-M4K220Exp), USG, GI Endoscopy, and CV Intervention systems.
The territories specified in the agreement are detailed below:
| Zone | States/Territories Covered |
|---|---|
| Western Zone | Rajasthan, Gujarat, Maharashtra, Goa, Diu, Daman, Dadra Nagar Haveli, and Silvassa. |
| South Zone | Karnataka, Andhra Pradesh, Telangana, Tamilnadu, Kerala, and Puducherry. |
The terms of the agreement stipulate that there is no consideration paid or received in this transaction. The commitment to the partnership is set for a duration until March 31, 2027, and is subject to renewal on an annual basis.
This strategic arrangement is expected to significantly benefit Aprameya Medtech Private Limited by enabling market penetration across both the Western and Southern Regions of India. Furthermore, the agreement provides a distinct advantage to the company as it progresses with its own manufacturing plans before full production commences.
APRAMEYA Stock Price Movement
Today, Aprameya Engineering Limited shares edged higher, concluding the trading session at ₹160.00 after gaining 0.66%. The stock saw trading volume stand at 12,000 shares, charting between an intraday low of ₹158 and a high of ₹162.5.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.